Michael Glover, MD

Peer-Reviewed Articles

1. Jiang CY, Hwang H, Epstein IY, Bakaloudi DR, Talukder R, Taylor AK, Nizam A, Jindal T, Glover MJ, Khaki AR, Barata PC, Nguyen CB, Oh E, Davis NB, Mabey H, Hoimes CJ, Evans ST, Abuqayas B, Lemke E, Tsung I, Qiao W, Kilari D, Zakharia Y, Bilen MA, Milowsky MI, Shah SA, Gupta S, Emamekhoo H, Bellmunt J, Alva AS, Grivas P, Msaouel P, Koshkin VS, Campbell MT, Alhalabi O. Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study. Oncologist 30(11), 2025. e-Pub 2025. PMID: 41056445.
2. Glover MJ, Ashok A, Khan O, Kao CS, Chiang R, Hoerner CR, Shah SA, Srinivas S, Fan AC, Khaki AR. Genomic Landscape and Outcomes of Renal Cell Carcinoma With Metastases to the Pancreas. JCO Precis Oncol 9:e2500318, 2025. e-Pub 2025. PMID: 41197084.
3. Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. Urol Oncol, 2025. e-Pub 2025. PMID: 41152111.
4. Nizam A, Nguyen CB, Li J, Zabor EC, Msaouel P, Jiang CY, Alhalabi O, Oh E, Davidsohn MP, Epstein IB, Bakaloudi DR, Talukder R, Jindal T, Taylor AK, Glover MJ, Khaki AR, Lemke E, Mabey H, Abuqayas B, Jang A, Brown JR, Evans ST, Pywell C, Basu A, Bilen MA, Barata PC, Zakharia Y, Milowsky MI, Kilari D, Hoimes CJ, Shah SA, Emamekhoo H, Davis NB, Gupta S, Grivas P, Bellmunt J, Campbell MT, Alva AS, Koshkin VS. Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study. Cancer Med 14(19):e71284, 2025. e-Pub 2025. PMID: 41031719.
5. Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol 8(2):258-262, 2025. e-Pub 2025. PMID: 39709257.
6. Sfakianos JP, Basu A, Laliotis G, Cumarasamy S, Rich JM, Kommalapati A, Glover M, Mahmood T, Tillu N, Hoimes CJ, Selig G, Kollipara R, Stewart TF, Rivero-Hinojosa S, Dutta P, Calhoun M, Sharma S, Malhotra M, ElNaggar AC, Liu MC, Ferguson JE 3rd, Diniz M, Mehrazin R, Wiklund P, Tan A, Shah S, Galsky MD. Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. Eur Urol Oncol 8(2):306-314, 2025. e-Pub 2025. PMID: 39013741.
7. Glover M, Beshar I, McHenry A, Ding C, Dorigo O, Chan E, Shah SA. Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report. Case Rep Oncol 18(1):473-479, 2025. e-Pub 2025. PMID: 40235861.
8. Singhal S, Dickerson J, Glover MJ, Roy M, Chiu M, Ellis-Caleo T, Hui G, Tamayo C, Loecher N, Wong HN, Heathcote LC, Schapira L. Patient-reported outcome measurement implementation in cancer survivors: a systematic review. J Cancer Surviv 18(2):223-244, 2024. e-Pub 2024. PMID: 35599269.
9. El Zarif T, Nassar AH, Pond GR, Zhuang TZ, Master V, Nazha B, Niglio S, Simon N, Hahn AW, Pettaway CA, Tu SM, Abdel-Wahab N, Velev M, Flippot R, Buti S, Maruzzo M, Mittra A, Gheeya J, Yang Y, Rodriguez PA, Castellano D, de Velasco G, Roviello G, Antonuzzo L, McKay RR, Vincenzi B, Cortellini A, Hui G, Drakaki A, Glover M, Khaki AR, El-Am E, Adra N, Mouhieddine TH, Patel V, Piedra A, Gernone A, Davis NB, Matthews H, Harrison MR, Kanesvaran R, Giudice GC, Barata P, Farolfi A, Lee JL, Milowsky MI, Stahlfeld C, Appleman L, Kim JW, Freeman D, Choueiri TK, Spiess PE, Necchi A, Apolo AB, Sonpavde GP. Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. J Natl Cancer Inst 115(12):1605-1615, 2023. e-Pub 2023. PMID: 37563779.
10. Moey MYY, Hennessy C, French B, Warner JL, Tucker MD, Hausrath DJ, Shah DP, DeCara JM, Bakouny Z, Labaki C, Choueiri TK, Dent S, Akhter N, Ismail-Khan R, Tachiki L, Slosky D, Polonsky TS, Awosika JA, Crago A, Wise-Draper T, Balanchivadze N, Hwang C, Fecher LA, Gomez CG, Hayes-Lattin B, Glover MJ, Shah SA, Gopalakrishnan D, Griffiths EA, Kwon DH, Koshkin VS, Mahmood S, Bashir B, Nonato T, Razavi P, McKay RR, Nagaraj G, Oligino E, Puc M, Tregubenko P, Wulff-Burchfield EM, Xie Z, Halfdanarson TR, Farmakiotis D, Klein EJ, Robilotti EV, Riely GJ, Durand JB, Hayek SS, Kondapalli L, Berg S, O'Connor TE, Bilen MA, Castellano C, Accordino MK, Sibel B, Weissmann LB, Jani C, Flora DB, Rudski L, Dutra MS, Nathaniel B, Ruiz-Garcia E, Vilar-Compte D, Gupta S, Morgans A, Nohria A. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Transl Oncol 34:101709, 2023. e-Pub 2023. PMID: 37302348.
11. Johnson DB, Atkins MB, Hennessy C, Wise-Draper T, Heilman H, Awosika J, Bakouny Z, Labaki C, Saliby RM, Hwang C, Singh SRK, Balanchivadze N, Friese CR, Fecher LA, Yoon JJ, Hayes-Lattin B, Bilen MA, Castellano CA, Lyman GH, Tachiki L, Shah SA, Glover MJ, Flora DB, Wulff-Burchfield E, Kasi A, Abbasi SH, Farmakiotis D, Viera K, Klein EJ, Weissman LB, Jani C, Puc M, Fahey CC, Reuben DY, Mishra S, Beeghly-Fadiel A, French B, Warner JL. Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. BMC Cancer 23(1):265, 2023. e-Pub 2023. PMID: 36949413.
12. Bakouny Z, Labaki C, Grover P, Awosika J, Gulati S, Hsu CY, Alimohamed SI, Bashir B, Berg S, Bilen MA, Bowles D, Castellano C, Desai A, Elkrief A, Eton OE, Fecher LA, Flora D, Galsky MD, Gatti-Mays ME, Gesenhues A, Glover MJ, Gopalakrishnan D, Gupta S, Halfdanarson TR, Hayes-Lattin B, Hendawi M, Hsu E, Hwang C, Jandarov R, Jani C, Johnson DB, Joshi M, Khan H, Khan SA, Knox N, Koshkin VS, Kulkarni AA, Kwon DH, Matar S, McKay RR, Mishra S, Moria FA, Nizam A, Nock NL, Nonato TK, Panasci J, Pomerantz L, Portuguese AJ, Provenzano D, Puc M, Rao YJ, Rhodes TD, Riely GJ, Ripp JJ, Rivera AV, Ruiz-Garcia E, Schmidt AL, Schoenfeld AJ, Schwartz GK, Shah SA, Shaya J, Subbiah S, Tachiki LM, Tucker MD, Valdez-Reyes M, Weissmann LB, Wotman MT, Wulff-Burchfield EM, Xie Z, Yang YJ, Thompson MA, Shah DP, Warner JL, Shyr Y, Choueiri TK, Wise-Draper TM. Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncol 9(1):128-134, 2023. e-Pub 2023. PMID: 36326731.
13. Chiang RS, Desai A, Glover MJ, Hui G, Ramchandran KJ, Wakelee H, Lythgoe MP, Khaki AR. Racial Diversity and Reporting in United States Food and Drug Administration Registration Trials for Thoracic Malignancies from 2006 to 2020. Cancer Invest 41(1):43-47, 2023. e-Pub 2023. PMID: 36197034.
14. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 128(6):1194-1205, 2022. e-Pub 2022. PMID: 34882781.
15. Glover M, Hui G, Chiang R, Savage P, Krell J, Julve M, Grivas P, Lythgoe M, Khaki AR. Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021. BJU Int 129(2):168-170, 2022. e-Pub 2022. PMID: 34748278.
16. Hawley JE, Sun T, Chism DD, Duma N, Fu JC, Gatson NTN, Mishra S, Nguyen RH, Reid SA, Serrano OK, Singh SRK, Venepalli NK, Bakouny Z, Bashir B, Bilen MA, Caimi PF, Choueiri TK, Dawsey SJ, Fecher LA, Flora DB, Friese CR, Glover MJ, Gonzalez CJ, Goyal S, Halfdanarson TR, Hershman DL, Khan H, Labaki C, Lewis MA, McKay RR, Messing I, Pennell NA, Puc M, Ravindranathan D, Rhodes TD, Rivera AV, Roller J, Schwartz GK, Shah SA, Shaya JA, Streckfuss M, Thompson MA, Wulff-Burchfield EM, Xie Z, Yu PP, Warner JL, Shah DP, French B, Hwang C. Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Netw Open 5(1):e2142046, 2022. e-Pub 2022. PMID: 34982158.
17. Wu JT, Kwon DH, Glover MJ, Henry S, Wood D, Rubin DL, Koshkin VS, Schapira L, Shah SA. Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. JCO Oncol Pract 17(3):e377-e385, 2021. e-Pub 2021. PMID: 33332170.
18. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, Shete S, Hsu CY, Desai A, de Lima Lopes G Jr, Grivas P, Painter CA, Peters S, Thompson MA, Bakouny Z, Batist G, Bekaii-Saab T, Bilen MA, Bouganim N, Larroya MB, Castellano D, Del Prete SA, Doroshow DB, Egan PC, Elkrief A, Farmakiotis D, Flora D, Galsky MD, Glover MJ, Griffiths EA, Gulati AP, Gupta S, Hafez N, Halfdanarson TR, Hawley JE, Hsu E, Kasi A, Khaki AR, Lemmon CA, Lewis C, Logan B, Masters T, McKay RR, Mesa RA, Morgans AK, Mulcahy MF, Panagiotou OA, Peddi P, Pennell NA, Reynolds K, Rosen LR, Rosovsky R, Salazar M, Schmidt A, Shah SA, Shaya JA, Steinharter J, Stockerl-Goldstein KE, Subbiah S, Vinh DC, Wehbe FH, Weissmann LB, Wu JT, Wulff-Burchfield E, Xie Z, Yeh A, Yu PP, Zhou AY, Zubiri L, Mishra S, Lyman GH, Rini BI, Warner JL. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395(10241):1907-1918, 2020. e-Pub 2020. PMID: 32473681.
19. Glover M, Mansoor E, Panhwar M, Parasa S, Cooper GS. Epidemiology of Colorectal Cancer in Average Risk Adults 20-39 Years of Age: A Population-Based National Study. Dig Dis Sci 64(12):3602-3609, 2019. e-Pub 2019. PMID: 31175493.
20. Glover M, Soni S, Ren Q, Maclennan GT, Fu P, Gupta S. Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens. Oncol Lett 14(4):3927-3934, 2017. e-Pub 2017. PMID: 28943900.

Review Articles

1. Glover MJ, Bien J, Chen CT. Toward Precision Perioperative Therapy in GI Malignancies. JCO Precis Oncol 7:e2200381, 2023. e-Pub 2023. PMID: 37625103.
2. Elkrief A, Wu JT, Jani C, Enriquez KT, Glover M, Shah MR, Shaikh HG, Beeghly-Fadiel A, French B, Jhawar SR, Johnson DB, McKay RR, Rivera DR, Reuben DY, Shah S, Tinianov SL, Vinh DC, Mishra S, Warner JL. Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. Cancer Discov 12(2):303-330, 2022. e-Pub 2022. PMID: 34893494.
3. Chiang RS, Glover MJ, Khaki AR, Srinivas S. Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab. Onco Targets Ther 15:1259-1269, 2022. e-Pub 2022. PMID: 36275184.

Abstracts

1. Glover. Expression of Bcl-2 and PCNA in Prostate Needle Biopsy Specimens.
2. Soni, Glover, Ren, Maclennnan, Fu, Gupta. Chronic Inflammation Contributes to Neoplastic Progression in Prostate Tissue: A Needle Biopsy Study. American Association of Cancer Research Conference 2017.
3. Wang, Buzzy, Mahran, Glover, Abboud, Janaki, Turk, Ponsky. Correlation of Low-Grade Radical Prostatectomy Histopathology Lesion Characteristics to MRI PI-RADS Impression. Society for Urologic Oncology 2017.
4. Glover. Evaluating neuroendocrine differentiation and its clinical significance in Radical Prostatectomy Specimen. Association of Indian Physicians of Northern Ohio conference.
5. Glover M, Abboud, Mahran, Buzzy, Thawani, Wang, Gulani, Ponsky, Jaeger. MP23-21 The Impact of mpMRI on Prostate Cancer Detection With Respect to Prostate Volume 51(S2).
6. Glover M, Wu, Kwon, Zhang, Henry, Wood, Rubin, Borno, Small, Schapira, Koshkin, Shah. Patterns in Cancer Management Changes for Patients with COVID-19 in Northern California. American Society of Clinical Oncology 2021.
7. Glover M, Mansoor, Cooper, Cummings. Epidemiology of Non-Malignant Gastrointestinal Disorders in Individuals with Cystic Fibrosis in USA from 2013 to 2018: A Population-Based National Study.
8. Glover M, Ewongo, Usoz, Komber, Bagshaw, Shah, Shah, Qian. Outcomes with neoadjuvant chemotherapy in bladder-preserving treatment. ASCO Genitourinary Symposium 2024.
9. Zhu, Chen, Glover, Shankar, MacLennan, Gupta. Abstract LB-255: Prognostic Role of Neuroendocrine Differentiation Marker in Prostate Adenocarcinoma. American Association of Cancer Research Conference 2017 77.
10. Glover, Mansoor, Cooper, Cummings. Epidemiology of Non-Malignant Gastrointestinal Disorders in Individuals with Cystic Fibrosis in USA from 2013 to 2018: A Population-Based National Study. American College of Gastroenterology.
11. Glover M, Chiang, Hoerner, Khan, Kao, Shah, Srinivas, Fan, Khaki. Renal cell carcinoma with metastasis to the pancreas. ASCO Genitourinary Symposium 2023.

Letters to the Editor

1. Jindal T, Jiang CY, Alhalabi O, Nguyen CB, Oh E, Tsung I, Bakaloudi DR, Talukder R, Davidsohn M, Freeman D, Epstein IY, Ding CC, Nizam A, Glover MJ, Khaki AR, Taylor AK, Lemke E, Jang A, Evans ST, Shin D, Pywell C, Basu A, Bilen MA, Zakharia Y, Barata P, Milowsky MI, Brown J, Kilari D, Emamekhoo H, Hoimes CJ, Shah S, Davis NB, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study. Eur Urol, 2025.